•  
  •  
  •  
  •  

2026-07-25 05:07:09

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%

Keywords Selected:  DivisLaboratories

Stock Report

  • USFDA inspects Unit 1 of Divi's Laboratories Limited
  • Divis Laboratories Ltd posts consolidated Q1FY26 PAT of Rs. 545 crores
  • Divi's Laboratories inks long term manufacturing and supply agreement with global pharma company
  • Divi's Laboratories Limited recommends final dividend of Rs. 30
  • Divi's Laboratories Ltd reports higher consolidated PAT of Rs. 662 crores
  • Divi's Laboratories signs long-term manufacturing and supply agreement with global pharma company
  • Divis Laboratories Ltd posts consolidated PAT of Rs. 430 crores in Q1FY25
  • USFDA completes cGMP inspection of Divi's Laboratories Limited's Unit 2
  • Divi's Laboratories Ltd to expand capacity at an outlay of Rs. 650 to Rs. 700 crores
  • Divis Laboratories Ltd posts Rs. 348 crores consolidated net profit in Q2 FY2024
  • USFDA Delegation visits Divi's Laboratories Limited's Unit I at Choutuppal, Telangana, India
  • Divi's Laboratories Limited recommends dividend of Rs. 30
  • Divi's Laboratories Limited Q4FY23 consolidated PAT marginally up QoQ at Rs. 320.97 crores
  • Divi's Laboratories Selects Juniper Networks for Automated Network Infrastructure Across Massive Pharma Manufacturing Facilities
  • Divis Laboratories Ltd posts consolidated Q3FY23 PAT of Rs. 306.80 crores
  • Divis Laboratories Ltd Q2 FY2023 consolidated profit declines to Rs. 493.60 crores
  • Divis Laboratories Ltd reports consolidated PAT of Rs. 702.01 crores in Q1 FY2023
  • Divi's Laboratories Ltd recommends dividend of Rs. 30
  • Divi's Laboratories Q4FY22 consolidated PAT slips QoQ to Rs. 894.64 crores
  • Divis Laboratories Ltd consolidated Q3FY22 PAT zooms to Rs. 902.24 crores
  • Divis Laboratories Ltd consolidated Q2FY22 PAT up at Rs. 606.46 crore

Latest Post

  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025